Drugs / SCG101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06617000 | Oct 2022 → Dec 2025 overdue | hepatocellular carcinoma | SCG Cell Therapy Pte. Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05339321 | Apr 2021 → Jul 2023 | hepatocellular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05417932 | Oct 2022 → Sep 2025 overdue | hepatocellular carcinoma | SCG Cell Therapy Pte. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCG101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05417932 ↗ |
| Modality | Cell therapy | “SCG101 is an autologous HBV-specific T cell receptor engineered T cell therapy.” NCT05339321 ↗ |
| Route | Intravenous | “SCG101 will be given via Intravenous (IV) infusion.” NCT05339321 ↗ |